Fecal transplant for immune-therapy diarrhea or bowel inflammation
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This early-phase study tests whether stool/fecal microbiota transplant (a fecal transplant) can help people who develop significant diarrhea or colitis after immune-checkpoint therapy. It aims to reduce bowel inflammation and improve symptoms, while carefully checking for infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have certain cancers (genitourinary, melanoma or skin cancers, lung/head-and-neck, sarcoma/lymphoma, GI/gynecologic/breast).
- You are (or were) being treated with an immune-checkpoint inhibitor (ICPI).
- You developed new diarrhea and/or colitis symptoms that are at least moderate (grade 2 or higher) within the last 45 days, and it’s mainly a gut problem (not another organ toxicity).
- Stool testing shows there’s no active stomach/gut infection around the time of treatment (or your doctor/infectious disease specialist clears you after testing and imaging).
- You may have used steroids or other immune medicines in the past only if they were stopped far enough ahead of the transplant (timing rules apply).
- You can sign consent, and you have an expected survival of more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
This trial tests whether a treatment called fecal microbiota transplant (FMT) — transferring healthy gut bacteria — can help relieve diarrhea and colitis caused by immunotherapy drugs. If you have melanoma or kidney cancer and are experiencing diarrhea after immunotherapy, this study may offer a new option.
This trial tests whether putting stool (fecal microbiota) from a donor into your bowel can improve symptoms in people with IBS who are not IBS-C. It may help by changing the gut bacteria that can influence IBS symptoms.
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
This trial studies fecal microbiota transplantation (a stool-based treatment) to improve symptoms and safety in people with certain gut and immune conditions. It aims to see whether changing gut bacteria can help you feel better.
This trial tests whether fecal microbiota transplantation (FMT) can safely and effectively treat mild to moderate ulcerative colitis over the long term. FMT involves transferring stool from a healthy donor to restore a healthy balance of gut bacteria.
Hear when a new Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.